TUS-PHARMA(SZ:000590) 中国基金报·2025-07-15 16:12Core Viewpoint - The article discusses the significant change in control of Qidi Pharmaceutical due to a judicial auction, where Hunan Sailuxian successfully acquired a 24.47% stake in the company for 1.007 billion yuan, potentially leading to a change in the company's controlling shareholder [2][9][18]. Summary by Sections Auction Details - The auction for Qidi Pharmaceutical's shares took place from July 14 to July 15, 2025, after a delay due to objections from interested parties [7]. - Hunan Sailuxian won the auction with a bid of 1.007 billion yuan, translating to an average price of 17.19 yuan per share, which is approximately 24% higher than the closing price on the auction day [9][18]. Company Background - Qidi Pharmaceutical, listed under the stock code 000590, has been facing financial difficulties, with a reported revenue of 343 million yuan in 2024, down 15.18% year-on-year, and a net loss of 125 million yuan, a staggering decline of 596.98% [18]. - Hunan Sailuxian was established on June 19, 2025, with a registered capital of 400 million yuan, primarily controlled by Jiang Xin, who is also the founder and chairman of Hunan Hengchang Pharmaceutical Group [12][15]. Strategic Implications - The acquisition is seen as a strategic move to enhance the supply chain and profitability, as Hunan Hengchang's distribution network complements Qidi Pharmaceutical's product offerings [16]. - If the share transfer is completed, Qidi Pharmaceutical's current controlling shareholder, Qidi Technology Service Co., will lose its controlling status, reducing its voting rights from 26.37% to 1.90% [18]. Market Reaction - Following the auction news, Qidi Pharmaceutical's stock experienced significant volatility, with a nearly 50% increase in price over the month leading up to the auction [19].